According to Zhizhong Finance APP, CHINARES PHARMA (03320) announced that between November 8, 2024, and December 18, 2024, the company's wholly-owned subsidiary CHINARES PHARMA Holdings accumulated the acquisition of an additional 5.0424 million shares of China Resources Boya Bio-pharmaceutical Group through the centralized competitive bidding trading system of the Shenzhen Stock Exchange, accounting for 1.00% of the total equity of China Resources Boya Bio-pharmaceutical Group.

As of the date of this announcement and after the above-mentioned shareholding increase, the company indirectly holds approximately 30.28% of the total equity and approximately 41.59% of the voting rights of China Resources Boya Bio-pharmaceutical Group through CHINARES PHARMA Holdings. China Resources Boya Bio-pharmaceutical Group is recorded as a subsidiary of the company.